Boston, United States
Poplar Therapeutics, underscored by the slogan "Toward Zero. Beyond Limits.", emerges as a frontrunner in the field of biotechnology, focused on pioneering immunology solutions. At its core, the company's ambition is to redefine allergic disease treatment through its innovative anti-IgE therapy. The lead program, PHB-050, stands as a testament to this vision. Its distinct triple-action design offers a next-generation solution for atopic diseases, demonstrating potential to drastically reduce IgE levels and ultimately improve patients' quality of life.
Despite the absence of a specified founding year or headquarters, Poplar Therapeutics has successfully captured investor interest, as evidenced by a significant $45.00M Series A investment on March 1, 2026. Esteemed investors such as RA Capital Management, ArrowMark Partners, Janus Henderson Investors, SR One, and Vida Ventures have committed substantial resources, signaling strong confidence in the company's potential to disrupt conventional allergic disease paradigms.
